|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00224809 |
Purpose
The Transesophageal Echocardiography (TEE) Surgical Treatment of Ischemic Heart Failure (STICH) ancillary study will define the mechanism(s) of functional mitral regurgitation (MR) by TEE in patients with ischemic cardiomyopathy, and the impact of therapy (medical, coronary artery bypass grafting [CABG], or CABG plus surgical ventricular restoration [SVR]) on mechanism and severity of MR. Severity of the effect of functional MR on clinical outcomes will also be examined. The TEE STICH study will address four specific aims that will focus on defining the following: 1) the mechanism(s) of functional MR in ischemic cardiomyopathy; 2) the effect of therapy on the mechanism and severity of functional MR; 3) myocardial viability on functional MR and its response to treatment; and 4) the effect of MR on prognosis in ischemic cardiomyopathy.
| Condition | Intervention |
|---|---|
|
Cardiovascular Diseases Heart Diseases Coronary Disease |
Drug: Angiotensin-Converting Enzyme Inhibitors Procedure: Coronary Artery Bypass Graft Drug: Angiotensin Receptor Blockers Drug: Spironolactone Drug: Aspirin Drug: Clopidogrel Procedure: Surgical Ventricular Restoration |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Factorial Assignment Primary Purpose: Prevention |
| Official Title: | Functional Mitral Regurgitation in STICH |
| Estimated Enrollment: | 250 |
| Study Start Date: | September 2002 |
| Study Completion Date: | May 2007 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| ClinicalTrials.gov Identifier: | NCT00224809 History of Changes |
| Other Study ID Numbers: | 266, R01 HL72430 |
| Study First Received: | September 21, 2005 |
| Last Updated: | December 11, 2007 |
| Health Authority: | United States: Federal Government |
|
Cardiovascular Diseases Coronary Disease Coronary Artery Disease Heart Diseases Mitral Valve Insufficiency Myocardial Ischemia Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases Heart Valve Diseases Aspirin Clopidogrel Enzyme Inhibitors Angiotensin-Converting Enzyme Inhibitors Spironolactone |
Angiotensin Receptor Antagonists Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |